HC Wainwright & Co. Reiterates Buy on Cartesian Therapeutics, Maintains $2 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Mitchell Kapoor has reiterated a Buy rating on Cartesian Therapeutics (NASDAQ:RNAC) and maintained a $2 price target.
March 11, 2024 | 10:47 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Mitchell Kapoor reiterates a Buy rating on Cartesian Therapeutics with a $2 price target.
The reiteration of a Buy rating and maintenance of a $2 price target by a reputable analyst like Mitchell Kapoor suggests a positive outlook for Cartesian Therapeutics. This endorsement could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100